Jubilant Therapeutics India Profile
Key Indicators
- Authorised Capital ₹ 86.65 Cr
as on 05-01-2025
- Paid Up Capital ₹ 86.65 Cr
as on 05-01-2025
- Company Age 5 Year, 10 Months
- Last Filing with ROC 31 Mar 2024
- Revenue 221.60%
(FY 2023)
- Profit 558.81%
(FY 2023)
- Ebitda 125.29%
(FY 2023)
- Net Worth 11.29%
(FY 2023)
- Total Assets 12.90%
(FY 2023)
About Jubilant Therapeutics India
The Company is engaged in the Healthcare Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 86.65 Cr and a paid-up capital of Rs 86.65 Cr, as per Ministry of Corporate Affairs (MCA) records.
The Key Managerial Personnel (KMP) at Jubilant Therapeutics India Limited India are Arun Sharma as CFO and Anil Sharma as Company Secretary. Sanjay Gupta, Shyam Pattabiraman, Arvind Chokhany, and One other member serve as directors at the Company.
- CIN/LLPIN
U74994UP2019PLC114901
- Company No.
114901
- Company Classification
Public Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2019
- Date of AGM
29 Aug 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Ghaziabad, Uttar Pradesh, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Jubilant Therapeutics India?
Executive Team (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Arun Sharma  | CFO | 18-Sep-2019 | Current |
| Anil Sharma | Company Secretary | 18-Sep-2019 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Sanjay Gupta | Director | 16-Jul-2021 | Current |
| Shyam Pattabiraman | Director | 08-Sep-2020 | Current |
| Arvind Chokhany | Director | 03-Jun-2021 | Current |
| Sridharan Rajagopal | Whole-Time Director | 15-May-2019 | Current |
Financial Performance of Jubilant Therapeutics India.
Jubilant Therapeutics India Limited, for the financial year ended 2023, experienced significant growth in revenue, with a 221.6% increase. The company also saw a substantial improvement in profitability, with a 558.81% increase in profit. The company's net worth Soared by an impressive increase of 11.29%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Jubilant Therapeutics India?
In 2023, Jubilant Therapeutics India had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Jubilant Therapeutics India?
Jubilant Therapeutics India has a workforce of 13 employees as of Apr 04, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Jubilant Therapeutics India, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Jubilant Therapeutics India's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
